Michael M. Rowe
Net Worth

Last updated:

What is Michael M. Rowe net worth?

The estimated net worth of Mr. Michael M. Rowe is at least $3,109,998 as of 4 Dec 2023. He owns shares worth $533,088 as insider and has received compensation worth at least $2,576,910 in Eyenovia, Inc..

What is the salary of Michael M. Rowe?

Mr. Michael M. Rowe salary is $368,130 per year as Chief Operating Officer in Eyenovia, Inc..

How old is Michael M. Rowe?

Mr. Michael M. Rowe is 63 years old, born in 1962.

What stocks does Michael M. Rowe currently own?

As insider, Mr. Michael M. Rowe owns shares in one company:

Company Title Shares Price per share Total value
Eyenovia, Inc. (EYEN) Chief Operating Officer 32,927 $16.19 $533,088

What does Eyenovia, Inc. do?

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

EYEN logo
EYEN
Eyenovia, Inc.
$16.19

Michael M. Rowe insider trading

Eyenovia, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock, par value $.0001 4,890 $1.36 $6,650
Purchase
Common Stock, par value $.0001 1,400 $1.66 $2,324
Purchase
Common Stock, par value $.0001 1,137 $1.75 $1,990
Option
Common Stock, par value $.0001 10,000 $2.72 $27,200
Option
Stock Option (right to buy) 10,000 $2.72 $27,200
Purchase
Common Stock, par value $.0001 10,000 $1.54 $15,400
Purchase
Common Stock, par value $.0001 1,200 $4.14 $4,968
Purchase
Common Stock, par value $.0001 1,500 $4.4 $6,600
Purchase
Common Stock, par value $.0001 1,400 N/A N/A
Purchase
Common Stock, par value $.0001 100 $3.84 $384
Purchase
Common Stock, par value $.0001 600 N/A N/A
Purchase
Common Stock, par value $.0001 200 N/A N/A

Eyenovia key executives

Eyenovia, Inc. executives and other stock owners filed with the SEC:

  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH (51) Chief Executive Officer, Pres, Chief Medical Officer & Director
  • Mr. John P. Gandolfo CPA (64) Chief Financial Officer & Sec.
  • Mr. Michael M. Rowe (63) Chief Operating Officer